

# CURRICULUM VITAE

**Ali Yaghobi Joybari**

*Radiation Oncologist*

*Tehran-IRAN*

*Associate Professor Of Shahid Beheshti University Of Medical Sciences*

# Curriculum Vitae



## Personal Information

<b>First Name:</b>	Ali
<b>Surname:</b>	Yaghobi Joybari
<b>Specialty:</b>	Radiation Oncology
<b>Academic Degree:</b>	MD, Associate Professor of Radiation Oncology
<b>Affiliation:</b>	Department of Radiation Oncology, school of medicine, Shahid Beheshti University Of Medical Science, Tehran, Iran
<b>Nationality:</b>	Iranian
<b>Year of Birth:</b>	1977
<b>Place of Birth:</b>	Ghaemshahr
<b>Marital Status:</b>	Married
<b>Personal Email :</b>	dryaghobii@yahoo.com
<b>Academic Email :</b>	dryaghobi@sbmu.ac.ir
<b>Website :</b>	www.dryaghobi.com
<b>Phone:</b>	09122013572
<b>Work Office:</b>	Department of Radiation Oncology, Emam Hosein Hospital, Madani Ave, (Tel: 021-73430)

## Educational Background

- 1996:** Admission to the Faculty of Medicine, Shahid Beheshti University of Medical Sciences
- 2003:** Received a doctorate in General Medicine
- 2006:** Entry to the specialty course
- 2009:** Obtaining a specialized certificate in the field of Radiotherapy-Oncology from Shahid Beheshti University of Medical Sciences
- 2010:** Obtaining a specialized board in the field of Radiotherapy - Oncology
- 2010:** Member of the faculty of the Department of Radiotherapy-Oncology, Shahid Beheshti University of Medical Sciences, Imam Hossein Hospital

## Skills

- Complete computer proficiency
- Familiarity with operating systems: Windows (XP, Vista, Seven) and Macintosh
- Familiarity with software package (Word, PowerPoint, Excel) office
- Ability to use the Internet and access to scientific articles of the day in full
- Ability to design a website
- Familiarity with information processing in SPSS software
- Persian and English typing

## Foreign Languages

- Full command of English
- Learning French
- Arabic

## Familiarity with the basics

- Curriculum writing
- Writing articles in Persian
- Writing articles in English
- Tariff writing

## **Full mastery of clinical medical examinations**

- Clinical evaluation by the OSCE test
- Principles of designing four-choice questions

## **Membership**

1. **Member of the Council of Representation of Medical Students of Mehr 75 Shahid Beheshti University of Medical Sciences 76-78**
2. **Member of the Central Council of the Student Council (Guild) of Shahid Beheshti University of Medical Sciences 77-80**
3. **Head of the Electoral Committee of the Student (Guild) Council of Shahid Beheshti University of Medical Sciences 77-80**
4. **Active member of the Iranian Radiotherapy-Oncology Association since 2006**
5. **Active member of the Iranian Cancer Society since 2007**
6. **Member of the faculty of the Department of Radiotherapy-Oncology, Shahid Beheshti University of Medical Sciences since 2008**
7. **Official member of the European Medical Association ESMO (membership number 73654)**
8. **Member of the Editorial Board of the Scientific Journal of the Iranian Pathological Association (in Persian)**
9. **Secretary of Oncology Scientific Journal of Iranian Pathology Association (in Persian)**
10. **Scientific Secretary of the Analytical Scientific News Magazine of the Iranian Cancer Society (in Persian and English)**
11. **Member of the judging committee of the Iranian Journal of Pathology**
12. **Secretary of the Education Committee of the Iranian Cancer Society**
13. **Interconnection of Oncology Radiotherapy Department of Shahid Beheshti University of Medical Sciences with the Office of Continuing Education**
14. **Member of the Question Design Committee of the Oncology Radiation Assistance Promotion Test at Shahid Beheshti University of Medical Sciences**

- 15. The main member of the organizer of the OSCE in-university exams in the field of oncology radiotherapy in 2010, Shahid Beheshti University of Medical Sciences**
- 16. Collaborating member in compiling the audit booklet of the specialized field of oncology radiotherapy developed by the Scientific Association of Oncology Radiotherapy**
- 17. Collaborating member in compiling an audit booklet on the field of oncology developed by the Iranian Scientific Association of Cancer**
- 18. Member of the Scientific-Specialized Committee for Error Analysis of Shahid Beheshti University of Medical Sciences on behalf of the Oncology Radiotherapy Department**
- 19. Member of the tariff writing group of the Iranian Oncology Radiotherapy Association in compiling radiotherapy codes for coding Iran's oncology radiotherapy services**
- 20. Connection of Oncology Radiotherapy Department of Shahid Beheshti University of Medical Sciences with the Research Vice Chancellor of the Faculty of Medicine**
- 21. Member of the Tariff Committee of the Iranian Oncology Radiotherapy Association**
- 22. Member of the Scientific Committee of the Iranian Oncology Radiotherapy Association**
- 23. Member of the Curriculum Committee of the Radiotherapy-Oncology Department of the Iranian Oncology Radiotherapy Association**
- 24. In charge of the examination committee of the Oncology Radiotherapy Department of Shahid Beheshti University of Medical Sciences since 2017**
- 25. Member of the Strategic Committee of the Radiotherapy-Oncology Department of Shahid Beheshti University of Medical Sciences since 2017**
- 26. Member of the Recruitment Committee of the Radiotherapy-Oncology Department of Shahid Beheshti University of Medical Sciences since 2017**

27. Member of the Guideline Committee of Oncology in Ministry of Health since 2017
28. Member of the Guideline Committee of Uro oncology in SBMU kidney research center since 2016
29. Member of Board Directed of Iranian Society of Radiation Oncology from 2020
30. Member of Board Directed of Shafa Teb Karmania Company from 2018
31. Chief Executive Officer of Shafa Teb Karmania Company from 2020
- 32.

### **Thesis (THESIS):**

#### **I. To receive a General Doctorate**

1. Bone Densitometry in Tehran population

#### **II. - To receive a Specialized Doctorate**

1. Comparison of 5FU-based chemoradiation with and without Eloxatin on Pathologic Complete Response in Neoadjuvant Chemoradiation of Rectal cancer

The article extracted from this dissertation, in addition to being published in the Iranian Journal of Pathology, won the top rank in the 5th Annual Congress of the Iranian Cancer Society.

#### **III. Thesis Supervisor**

1. **Zandian, Roya**, Comparison of taxol/carboplatin vs. cisplatin/5-fluorouracil regimens in definitive chemoradiotherapy for clinical complete response in patients with esophageal cancer
2. **Zamani, Jalal**, Evaluation of DFS Between weekly & 3-weeks paclitaxel chemotherapy in adjuvant breast cancer

3. **Jozian, Fariba**, The value of DW-MRI in predicting pathologic complete response (pCR) after neoadjuvant chemoradiation in patient with rectal cancer who referred to Imam Hossein hospital during July 2018 to July 2019
4. **Behzadi, Behnaz**, Evaluation of treatment outcomes of induction chemotherapy and then Neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer
5. **Arjmand, Yasaman**, Evaluation of Estrogen, Progesterone & HER2 receptor in Iranian population of Breast Cancer

#### IV. Thesis Advisor & Consultant

1. **Ghiasi, Hoseinali**, The impact of capecitabine on fingerprints in patients treated with this drug
2. **Rajabzadeh, Mania**, A comparison survey on the combination Aprepitant - dexamethasone - Ondansetron, vs. Placebo-dexamethasone - Ondansetron, for prevention of Moderate Emetogenic Chemotherapy Regimens-Induced Nausea and Vomiting,
3. **Babaei, Siamak**, HPV incidence in patients with rectal adenocarcinoma and its correlation with Disease Free Survival, Mutant KRAS and BRAF gene expression profiles in Iranian colorectal cancer patients
4. **Mansouri, Hamdollah**, the predictive value of cardiac biochemical markers including high sensitive cardiac troponin-I (HSCT-I), NT-Pro-BNP and two dimensional echocardiography in early detection of acute and sub acute cardiac toxicity in patients who are treated by anthracycline drug
5. **Khoshnoudi, Hojjat**, Mutant KRAS and BRAF gene expression profiles in Iranian colorectal cancer patients

#### PUBLICATION

##### I. Articles published in scientific journals:

###### A-Written in English:

1. **Yaghobi, Ali** , Azadeh, Payam, Moghadam , Shiva, Shafaghi, Behrouz, Primary Stromal sarcoma of the breast with nodal recurrence, Iranian Journal of Pathology, Iranian Journal of Pathology (2010)5 (1), 43- 46.

2. **Yaghobi, Ali** , Azadeh, Payam, Sheibani , Kh.M, Foudazi , M., Shafaghi, B. , Davaei, M., Comparison of 5FU-based chemoradiation with and without Eloxatin on Pathologic Complete Response in Neoadjuvant Chemoradiation of Rectal cancer, *Iranian Journal of Pathology* (2011) 6(3):110-116.
3. Azadeh , Payam, **Yaghobi, Ali**, Amini, Afshin, Farasatinasab, Maryam  
Paclitaxel-Induced Fingerprints Loss, *Annals of Pharmacotherapy*, 2014, vol48 (9) 1249-1250.
4. Azadeh, Payam, Hassanzadeh Rad, Babak, **Yaghobi, Ali** , Orbital Metastasis From Breast Cancer Without Significant Changes In CT Scan And MRI , *Iranian Journal Of Radiology* , 2016 , 13(2):e20004.
5. **Yaghobi, Ali**, Azadeh, Payam, Von Hippel-Lindau Disease with Multi-Organ Involvement: A Case Report and 8-Year Clinical Course with Follow-Up , *Am J Case Rep*, 2017, 18: 1220-1224.
6. **Yaghobi, Ali**, Sarbaz, Samaneh, Azadeh, Payam, Mirafsharieh, S.Abbas , Rahbari , Ali, Farasatinasab, Maryam, Mokhtari, Majid, Oxaliplatin-Induced Renal Tubular Vacuolization, *Annals Of Pharmacotherapy*, 2014,vol48(6) 796-800.
7. Azadeh, Payam, **Yaghobi, Ali**, Sarbaz, Samaneh, Ghiasi, Hosein Ali, Farasatinasab, Maryam, Solitary Psoas Muscle Metastasis Of Gastroesophageal Junction, Adenocarcinoma , *Iranian Journal of Pathology*, 2015
8. **Yaghobi, Ali**, Azadeh, Payam, Nemati Honar, Behzad, Cutaneous Verrucous Carcinoma superimposed on Chronically Inflamed Ileostomy Site Skin, a case report, , *Iranian Journal of Pathology*, 2018, 13(2): 209-217.
9. Azadeh, Payam, Rakhashani , Nasser, **Yaghobi, Ali**, Gorji Bayani, Pegah, Sarbaz, Samaneh, Farasatinasab , Maryam, Jaw Pain as a First Presentation in the Diagnosis of Breast Cancer , *Iranian Journal of Pathology*, 2016; 11(5): 439-442.
10. Azadeh, Payam , Khavidaki , Simin Dashti, **Yaghobi, Ali** , Sarbaz , Samaneh, Jafari , Atefeh, Yaseri, Mehdi, Amini, Afshin, Farasatinasab,



Maryam, Fingerprint changes among cancer patients treated with paclitaxel , J Cancer Res Clin Oncol , published online 2016

11. **Yaghobi, Ali**, Azadeh, Payam , Babaei, Siamak, Hosseini Kamal , Farnaz, Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer pathology and oncology research, 2019, 25(4): 1599-1605

12. **Yaghobi, Ali**, Azadeh, Payam. Ghiasi , Hosein A., Amouzegar, Atefeh , Yaseri , Mehdi, Amini, Afshin , Farasatinasab3, Maryam, Mokhtari, Majid, Capecitabine induced fingerprint changes, journal of clinical pharmacy and therapeutics , 2019, 44(5):780-787.

13. Yousefi Moteghaed, Niloofar , **Yaghobi, Ali** , Mostaar, Ahmad, Pseudo-CT Generation for External Radiotherapy Planning from Magnetic Resonance Imaging Data on Brain Regions , , Iranian Journal of Radiology, 2019, 16(3):e82804

14. Mostaar, Ahmad, **Yaghobi, Ali**, Medical Image Fusion Using BEMD and an Efficient Fusion Schema, Journal of Biomedical Physics and Engineering , 2018

15. Rezapour, Jafar, Paydar, Reza, Mostaar, Ahmad, **Yaghobi, Ali**, Comparison of breast absorbed dose in conventional and digital mamography machines in the actual condition used in Tabriz , Research in Medicine 2018, 42(1): 40-45

16. Haddad, Peiman , Zali, Alireza, Tabatabaeefar, Morteza, Nikoofar, Alireza , Hadizadeh Kharazi, Homayoun, Ghadyani, Mojtaba Fadavi , Pedram , Vossough, Parvaneh, Mousavizadeh, Mirahmad, Mehdizadeh , Mahshid, Motlagh, Ali, Amoozegar Hashemi, Farnaz, Ameri, Ahmad , **Yaghobi, Ali**, Turning Interdisciplinary Brain Tumor Science into Survival; Report from the Neuro-Oncology Scientific Club Opening Session, NOSC 2012 -19 January- Tehran, IR Iran Report and Opinion, 2012;4:(2)

**B-Written in Persian:**

1. **Yaghobi, Ali**, Herceptin treatment in gastro esophageal adenocarcinoma, Iranian Journal of Pathology, November 30, 2009 (consecutive 40)
2. **Yaghobi, Ali**, CDX2, CK7, CK20, CDX2 Useful markers for distinguishing colorectal metastatic carcinoma with ovarian involvement from primary ovarian adenocarcinoma , Iranian Journal of Pathology, Azar and D89 (consecutive 41)
3. **Yaghobi, Ali**, Pathological evaluation of TME rectal cancer sample, Iranian Journal of Pathology, April and May 1990 (consecutive 43)
4. **Yaghobi, Ali**, Treatment and prophylaxis of VTE in cancer patients: Commentary agreed by the main guidelines in the eighth issue of the Scientific-News Magazine of the Iranian Cancer Society
5. **Yaghobi, Ali**, Prevention, diagnosis and treatment of VTE in cancer patients in the book How to deal with oncology emergencies of the Iranian Cancer Society
6. **Yaghobi, Ali**, New biological and diagnostic factors predicting the results of treatment in early stage breast cancer, Iranian Journal of Pathology, June and July 1990 (consecutive 44)
7. **Yaghobi, Ali**, Targeted value-added therapy in oncology, Iranian Journal of Pathology, August and September 1990 (consecutive 45)
8. **Yaghobi, Ali**, IHC's position in the diagnosis of metastatic carcinoma of unknown origin (CUP), Iranian Journal of Pathology, Mehr and Aban 90 (consecutive 46)
9. **Yaghobi, Ali**, Gastrointestinal Stromal Tumors (GIST), Iranian Journal of Pathological Association, Bahman and Esfand 90 (consecutive 48)
10. **Yaghobi, Ali**, Diagnosis of pancreatic tumors by (EUS), Iranian Journal of Pathology, April and May 1991 (consecutive 49)
11. **Yaghobi, Ali**, Molecular mechanism of resistance to cytotoxic resistance, Iranian Journal of Pathology, Esfand 92 (consecutive 56)
12. **Yaghobi, Ali**, Hepatocellular carcinoma, Journal of the Iranian Society of Pathology, Esfand 92 91 (consecutive 59.60)
13. **Yaghobi, Ali**, Treatment and prophylaxis of venous thromboembolism in cancer patients, Iranian Journal of Pathology, July 1993 (consecutive, 6162)

14. **Yaghobi, Ali**, Agreed guidelines for the treatment of neuroendocrine tumors with hepatic metastasis, Iranian Journal of Pathology, August and September 1993 (consecutive 63)
15. **Yaghobi, Ali**, Non-functional pancreatic neuroendocrine tumors with good differentiation, Iranian Journal of Pathology Association, Azar and D 93 (consecutive 65)
16. **Yaghobi, Ali**, Therapeutic Strategies and Effective Mechanisms to Targeted Treatments in Small Non-Cellular Cancers, Iranian Journal of Pathology, 94 (consecutive 71)
17. **Yaghobi, Ali**, Should Dose Taxoter be an optional option in patients with metastatic prostate cancer, Iranian Journal of Pathology, Bahman and Esfand 94 (consecutive 72)
18. **Yaghobi, Ali**, A Review of Glioblastoma Multiform Treatment, Journal of Iranian Pathology Association, June and July 2016 (consecutive 74)
19. **Yaghobi, Ali**, Instructions and management of patients with metastatic colorectal cancer, Iranian Journal of Pathology, Bahman and Esfand 2016 (consecutive 78)
20. **Yaghobi, Ali**, treatment & diagnostic guideline in epithelial ovarian cancer, Iranian Journal of Pathology, khordad & Tir 2016 , (consecutive 80)
21. **Yaghobi, Ali**, change of treatment protocol in metastatic melanoma, Iranian Journal of Pathology, farvardin & ordibehesht 2018, (consecutive 85)
22. **Yaghobi, Ali**, metastatic breast cancer HR positive ,HER2 negative, Iranian Journal of Pathology, Bahman & Esfand 2019, (consecutive 85)
23. **Yaghobi, Ali**, Immuno oncology fourth potent pillar in treatment of oncology, Iranian Journal of Pathology, khordad & Tir 2019, (consecutive 85)
24. **Yaghobi, Ali**, treatment strategy in advanced breast cancer, Iranian Journal of Pathology, Mehr & Aban 2019, (consecutive 85)
25. **Yaghobi, Ali**, integrity biomarkers & target therapy in management of metastatic colorectal cancer, Iranian Journal of Pathology, Bahman & Esfand 2020, (consecutive 85)
26. **Yaghobi, Ali**, what is ideal treatment in cancer of gastroesophageal junction ,farvardin & ordibehesht 2020 (consecutive 97)

27. **Yaghobi, Ali**, do you think what is ideal treatment for Gastroesophageal junction carcinoma ? (consecutive 98)

## II. books

1. **Yaghobi, Ali**, Azadeh, Payam, Chemotherapy book, Clinical Guide For Patients & Families Volume 1, , Ali, Arjmand Publications, 2013
2. **Yaghobi, Ali**, Azadeh, Payam, Chemotherapy book, Clinical Guide For Patients & Families Volume 1, Arjmand Publications, 2015, Second Edition
3. **Yaghobi, Ali**, Azadeh, Payam Chemotherapy book, Clinical Guide For Patients & Families Volume 1, , Ali, Arjmand Publications, 2016, Third Edition
4. **Yaghobi, Ali**, Azadeh, Payam Breast Cancer Book, Clinical Guide For Patients & Families Volume 2, Arjmand Publications, 2013
5. **Yaghobi, Ali**, Azadeh, Payam Radiotherapy book, Clinical Guide For Patients & Families Volume 3, Arjmand Publications, 2013
6. **Yaghobi, Ali**, Azadeh, Payam Radiotherapy book, Clinical Guide For Patients & Families Volume 3, Arjmand Publications, 2015, Second Edition
7. **Yaghobi, Ali**, Azadeh, Payam, Prostate Cancer Book, Clinical Guide For Patients & Families Volume 4, , , Arjmand Publications, 2013
8. **Yaghobi, Ali**, Azadeh, Payam, Colorectal Cancer Book, Clinical Guide For Patients & Families Volume 5, Colon Cancer , Ali Yaghobi Joybari ,Payam Azadeh, Arjmand Publications, 2013
9. **Yaghobi, Ali**, Azadeh, Payam, Cancer Pharmacotherapy book, the first volume , Chemotherapy Agents, Clinical Guide For Patients & Families Volume 6, , Ali Yaghobi Joybari , Maryam Farasati nasab , Payam Azadeh, Arjmand Publications, 2013
10. **Yaghobi, Ali**, Azadeh, Payam, Farasati nasab, Maryam, Cancer Pharmacotherapy book, Second Volume, Targeted Therapy for Cancer,

- Clinical Guide For Patients & Families Volume 7, Payam Azadeh, Arjmand Publications, 2013
11. **Yaghobi, Ali**, Azadeh, Payam, Farasati nasab, Maryam Cancer Pharmacotherapy book, third Volume, Hormone Therapy for Cancer, Clinical Guide For Patients & Families Volume 8, Arjmand Publications, 2013
  12. **Yaghobi, Ali**, Azadeh, Payam, Pancreatic Cancer Book ,Clinical Guide For Patients & Families Volume 9, Arjmand Publications, 2014
  13. **Yaghobi, Ali**, Azadeh, Payam Esophageal Cancer Book ,Clinical Guide For Patients & Families Volume 10, Arjmand Publications, 2014
  14. **Yaghobi, Ali**, Azadeh, Payam Coping with Cancer book ,Clinical Guide For Patients & Families Volume 11, Arjmand Publications, 2014
  15. **Yaghobi, Ali**, Azadeh, Payam, Farasati nasab, Maryam, Marital Relationships in Cancer Patients Clinical Guide For Patients & Families Volume 12, Arjmand Publications, 2014
  16. **Yaghobi, Ali**, Azadeh, Payam Gastric Cancer Book, Clinical Guide For Patients & Families Volume 13, Arjmand Publications, 2015
  17. **Yaghobi, Ali**, Azadeh, Payam The Clinical Application of Blood Book, Clinical Guide For Patients & Families Volume 14, Arjmand Publications, 2015
  18. **Yaghobi, Ali**, Tizdast, Neda, Azadeh, Payam, Nutrition & Cancer Book , Clinical Guide For Patients & Families Volume 15, Arjmand Publications, 2014
  19. **Yaghobi, Ali**, Tizdast, Neda, Azadeh, Payam, Nutrition & Cancer Book , Clinical Guide For Patients & Families Volume 15, Arjmand Publications, Second Edition, 2017
  20. **Yaghobi, Ali**, Azadeh, Payam, Nemati Honar, Behzad, Pain & Cancer Book ,Clinical Guide For Patients & Families Volume 16, Arjmand Publications, 2014
  21. Taghizadeh, Ali, **Yaghobi, Ali**...[and etal], Principle Of Chemotherapy In Special Clinical Situation Book, , Arjmand Publications, 2014
  22. **Yaghobi, Ali**...[and etal], Thromboembolism & Cancer Book, , Arjmand Publications, 2014

### III. Slide

1. An overview of oncology radiotherapy reference books, including Perez's **Oncology Radiotherapy Book (2008)** and DeVita's **Clinical Oncology Book (2008)**, which includes (more than 20,000) 20,000 <slides that were reproduced as CDs and distributed in high circulation among oncologists

### Articles submitted to scientific congresses

#### I. Articles submitted to scientific congresses in the form of posters (POSTER):

1. **Primary Gastric Melanoma, in 3th Annual Congress of Iranian Cancer Association, Iran-Tehran**
2. **Primary high grade MALT Lymphoma of breast presented lymphoepithelial ulcer in 3th Annual Congress of Iranian Cancer Association, Iran-Tehran**
3. **Colorectal Cancer: Microsatellite Instability (MSI) Testing in 4th Annual Congress of Iranian Cancer Association, Iran-Tehran oct.22-24 2008**
4. **Meta-analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer: Secondary End Points in 4th Annual Congress of Iranian Cancer Association, Iran-Tehran oct.22-24 2008**

5. **Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in esophageal carcinoma: a meta-analysis.** in 4th Annual Congress of Iranian Cancer Association , Iran-Tehran oct.22-24 2008
6. **A case of sigmoid endometriosis difficult to differentiate from colon cancer** in 4th Annual Congress of Iranian Cancer Association, Iran-Tehran oct.22-24 2008
7. **Doctors Conclude Temeirolimus Is Effective New Treatment for Advanced Renal Cell Carcinoma** in 4th Annual Congress of Iranian Cancer Association, Iran-Tehran oct.22-24 2008
8. **What is Oncotype DX ®** in 4th Annual Congress of Iranian Cancer Association, Iran-Tehran oct.22-24 2008
9. **Gene Testing Predicts Response to Erbitux** in 4th Annual Congress of Iranian Cancer Association, Iran-Tehran oct.22-24 2008
10. **Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?** in 4th Annual Congress of Iranian Cancer Association , Iran-Tehran oct.22-24 2008
11. **Afinitor Earns FDA Approval for Advanced Kidney Cancer** in 5th Annual Congress of Iranian Cancer Association, Iran-Tehran oct.20-22 2009
12. **What's New in Chemotherapy Research?** in 5th Annual Congress of Iranian Cancer Association, Iran-Tehran oct.20-22 2009
13. **Metastatic Renal Cell Carcinoma** in 5th Annual Congress of Iranian Cancer Association, Iran-Tehran oct.20-22 2009
14. **Second-Line Treatment of Glioblastoma** in 5th Annual Congress of Iranian Cancer Association, Iran-Tehran oct.20-22 2009
15. **Glivec (imatinib) now approved in the UK for post surgery treatment of patients with KIT(CD117)-positive GIST, who are at significant risk of the cancer returning after surgery** in 3th Annual Congress of clinical oncology, Iran-Tehran Feb.3-4 2010
16. **Trastuzumab in HER2-positive advanced esophagogastric adenocarcinoma** in 3th Annual Congress of clinical oncology, Iran-Tehran Feb.3-4 2010
17. **Avastin delays progression of advanced ovarian cancer** in 6th Annual Congress of Iranian Cancer Association, Iran-Tehran Nov. 17-19 2010
18. **A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic masses** in 6th Annual Congress of Iranian Cancer Association, Iran-Tehran Nov. 17-19 2010

19. SATURN trial in 6th Annual Congress of Iranian Cancer Association, Iran-Tehran Nov. 17-19 2010
20. New treatment options in the management of glioblastoma multiform :a focus of bevacizumab in Annual Congress of clinical oncology, Iran-Tehran 2011
21. CK7, CK20, CDX2 and MUC2 immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma in Annual Congress of clinical oncology, Iran-Tehran 2011
22. Tarceva outperforms chemotherapy for initial treatment of lung cancer with an EGFR mutation in 7th Annual Congress of Iranian Cancer Association, Iran-Tehran Oct. 19 – 21 , 2011 , Iran-Tehran
23. Three years of adjuvant Imatinib may be the new standard of care for high risk patients with GIST in 7th Annual Congress of Iranian Cancer Association, Iran-Tehran Oct. 19 – 21 , 2011 , Iran-Tehran
24. Advisory committee recommends Everolimus for approval to treat advanced NET of pancreatic origin in 7th Annual Congress of Iranian Cancer Association, Iran-Tehran Oct. 19 – 21 , 2011 , Iran-Tehran
25. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer in 7th Annual Congress of Iranian Cancer Association, Iran-Tehran Oct. 19 – 21 , 2011 , Iran-Tehran
26. FDA approves Abiraterone for metastatic pancreatic cancer in 7th Annual Congress of Iranian Cancer Association, Iran-Tehran Oct. 19 – 21 , 2011 , Iran-Tehran
27. CAR T cell immunotherapy for human cancer in 1st National congress on inflammation ,Immunology and inflammatory disorders , 26 February 2019, Tehran
28. Cancer Treatment with Immune Checkpoint Inhibitors in 1st National congress on inflammation ,Immunology and inflammatory disorders , 26 February 2019, Tehran

## **II. Articles presented at the scientific congresses in the form of lectures (LECTURE):**

1. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials in 4th Annual Congress of Iranian Cancer Association, Iran-Tehran oct.22-24 2008



2. **Can Antibodies Help Cure Cancer?** in 5<sup>th</sup> Annual Congress of Iranian Cancer Association, Iran-Tehran oct.20-22 2009
3. **Comparison of 5FU-base chemoradiation with and without Eloxatin on Pathologic Complete Response in Neoadjuvant Chemoradiation of Rectal cancer** in 5<sup>th</sup> Annual Congress of Iranian Cancer Association, Iran-Tehran oct.20-22 2009

### **Scientific Congresses :**

#### **I. Lecture at Scientific Congresses**

1. **Lecture at the Conference on Treatment of Non-Melanoma Skin Tumors of the Iranian Association of Surgeons entitled: The role of radiotherapy in the treatment of non-melanoma skin cancers, / 10/88, Tehran**
2. **Lecture at the two-day seminar on the new Rectum Cancer of Shahid Beheshti University of Medical Sciences, entitled: Radiotherapy and modern methods in the treatment of rectal cancer, 5-4 / 12/89, Tehran**
4. **Lecture at the 35th Annual Congress of the Iranian Association of Surgeons Conference on Oncology entitled: update on metastatic breast cancer, 20-19 / 2/90, Tehran**
5. **Speech at the conference on how to deal with oncology emergencies of the Iranian Cancer Association ,entitled: Prevention, diagnosis and treatment of VTE in cancer patients, 3/5/90, Tehran**
6. **Lecture at the conference on how to deal with bladder tumors of the Iranian Urological Association with the title: The position of radiotherapy in the treatment of bladder cancers, 7/7/90, Tehran**
7. **Lecture at the Esophageal Cancer Conference of Shahid Beheshti University of Medical Sciences entitled: The position of Adjuvant and Neoadjuvant in the treatment of Esophageal Cancer, 7/14/90, Tehran**
8. **Lecture at the Conference of Iranian Association of Surgeons entitled: Dealing with Cervical Masses, 2/91, Tehran**
9. **Lecture at the Tehran Congress of Clinical Oncology entitled: Dealing with Oligodendroglioma Tumors, 9/91, Tehran**

10. Lecture at the Isfahan Congress of Clinical Oncology entitled: Fever and Neutropenia 10/92, Isfahan
11. Lecture at the Congress of Clinical Oncology of Tehran entitled: Chemotherapy in patients with renal failure, 93/7, Tehran
12. Lecture at Jihad Daneshgahi Breast Cancer Congress entitled: Drugs Used in Chemotherapy, 9/92, Tehran
13. Lecture at Jihad Daneshgahi Breast Cancer Congress entitled: Port and its care solutions, 8/93, Tehran
14. Lecture at the Congress of Urological Malignancies entitled: Treatment of Metastatic RCC, May 2015, Mashhad
15. Lecture at the Collective Congress of the University of Tehran entitled: Treatment of Re-Radiotherapy in Rectal Cancer, 3/94, Tehran
16. Lecture at the Cervical Cancer Congress, Azad University, entitled: Neo-Juvenile Therapy in Cervical Cancer, 5/94, Tehran
17. Lecture at the Immunology Conference of the Oncology Radiotherapy Association entitled: The Role of Immunoconology in Gastric Cancer, 2/96, Tehran
18. Lecture at the Immunoconferencing Conference of the Oncology Radiotherapy Association entitled: The Role of Immunoconology in Cancer NSCLC, 12/96, Tehran
19. Treatment induced cardiotoxicity
20. Lecture at Immunoconology conference of ISRO entitled: Immunotherapy in GI cancer , 17 may 2017, Tehran
21. Lecture at the Health Care Oncology Prostate Cancer Enlightening summit (HOPEs 7) entitled: Trend Use of adjuvant & salvage radiotherapy after Radical Prostatectomy and impact on long term survival results of 3 high volume centers over last two 2 decades, 2017, Muscat
22. Lecture at 1<sup>st</sup> National congress on inflammation ,Immunology and inflammatory disorders entitled: importance of prevention & early detection in cancer patients, 26 February 2019, Tehran
23. Lecture at 1<sup>st</sup> National congress on inflammation ,Immunology and inflammatory disorders entitled: different method of Immunoconology , 26 February 2019, Tehran
24. Lecture at 3<sup>rd</sup> international Clinical Oncology Conference of the Iranian Radiotherapy Society, entitled: Trend Use of adjuvant & salvage radiotherapy after Radical Prostatectomy and impact on long term survival , 2018 , Tehran

25.

## II. panel member at scientific conferences

1. Member of the panel for dealing with non-melanoma skin tumors of the Iranian Society of Surgeons, / 10/88, Tehran
2. Member of the panel for dealing with the Rectal Cancer of Shahid Beheshti University of Medical Sciences, 5-4 / 12/89, Tehran
3. Panel member How to deal with bladder tumor of Iranian Urological Association, 7/7/90, Tehran
4. Member of the panel dealing with esophageal cancer, Shahid Beheshti University of Medical Sciences, 7/14/90, Tehran
5. Member of the bladder preservation panel in Iranian Cancer Society Congress , 7/29/90, Tehran
6. Member of the panel of palliative care in common gastrointestinal cancers of the Scientific Society of General Surgeons of Iran, 13/8/90, Tehran
7. Member of the Standardization Panel of Pathological Reports of the Iranian Scientific Society of Pathology, 7/7/92, Tehran
8. Member of Lung Cancer Treatment Panel, 91, Uremia
9. Member of the panel entitled: Colon Cancer , in 4<sup>th</sup> International Gastro Intestinal Cancer Congress , , 21 Feb 2019, Tehran
10. Member of the panel entitled: Metastatic liver disease, in 3<sup>rd</sup> International Gastro Intestinal Cancer Congress , 21 Feb 2019, Tehran , 24th November 2016 , Tehran
11. Member of the panel entitled: Rectal Cancer (watch & wait strategy) ,in 18th Hematology & Oncology congress ,14 Nov 1019, Tehran

12. **Member of the panel entitled: Complicated Cases of Thyroid Carcinoma: Extended ,Metastatic ,Refractory, in 5th Head & Neck cancer congress, 31 July 2019, Tehran**
13. **Responsible member for site of radiotherapy in [www.radiotherapy.sbm.ac.ir](http://www.radiotherapy.sbm.ac.ir)**

### **III. Panel Coordinator at scientific conferences**

1. **Coordinator of panel entitled: management of cancer patient with history of cardiovascular disorder ,in cardio oncology congress , 3 October 2017 , Tehran**
2. **Coordinator of panel entitled: Recurrence Management of well-diff Thyroid Carcinoma: When? Why? How?, in 5<sup>th</sup> Head & Neck cancer congress, 31 July 2019, Tehran**
3. **Coordinator of panel entitled: Early Stage Breast Cancer , in Grand Round of ISRO , 28 August 2019, Tehran**
4. **Coordinator of panel entitled: Advance Breast cancer HER2 +, in Grand Round of ISRO , 28 August 2019, Tehran**
5. **Coordinator of panel entitled: PTE & VTE, in Grand Round of ISRO , 10 July 2019, Tehran**
6. **Coordinator of panel entitled: Metastatic Colon Cancer, in Grand Round of ISRO , 2020, kish**

### **IV. Webinar**

1. **Lecture at Actero conference entitled management of oncologic patient in covid 19 pandemic, 22 Apr, 2020**
2. **Coordinator of panel entitled: Oncology & Covid 19 (Present & Future) , 28 May 2020, Tehran**
3. **Member of the panel entitled: Review of Guideline update for drug PEG-Filgrastim**

**AWARDS:**

1. Awarded the top rank in the 4th Annual Congress of the Iranian Cancer Society for the article:

**Meta-Analysts of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer: Secondary End Points**

2. Awarded the top rank in the 5th Annual Congress of the Iranian Cancer Society for the article:

**Comparison of 5FU-based chemoradiation with and without Eloxatin on Pathologic Complete Response in Neoadjuvant Chemoradiation of Rectal cancer**

3. Awarded the highest rank in the 6th Annual Congress of the Iranian Cancer Society for the article:

**A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass**

**Holding Congresses And Scientific Seminars (courses and seminars celebration):**

1. Member of the Scientific and Executive Committee of the Third Annual Conference of the Iranian Cancer Association, 8/16/86, Tehran
2. Member of the Scientific and Executive Committee of the Fourth Annual Conference of the Iranian Cancer Association, 3-1 / 8/87, Tehran
3. Member of the Scientific and Executive Committee of the 5th Annual Conference of the Iranian Cancer Society, 8/30/30/88, Tehran
4. Member of the Scientific and Executive Committee of the 6th Annual Conference of the Iranian Cancer Association, 8/30/99, Tehran
5. Member of the Scientific and Executive Committee of the 7th Annual Conference of the Iranian Cancer Association, 8/10/30/89, Tehran
6. Member of the Scientific and Executive Committee of the First NET Conference of the Iranian Cancer Association / 4/88, Tehran
7. Member of the Scientific and Executive Committee of the Second NET Conference of the Iranian Cancer Association, 8/4/89, Tehran

- 8. Member of the Scientific and Executive Committee of the RCC Conference of the Iranian Cancer Association, 6/29/89, Tehran**
- 9. Member of the Scientific and Executive Committee of the GIST Conference of the Iranian Cancer Association, 7/22/89, Tehran**
- 10. Member of the Scientific and Executive Committee of the Annual Clinical Oncology Conference of the Iranian Radiotherapy Society, 10-29/30/89, Tehran**
- 11. Member of the Scientific and Executive Committee of the 3rd International Congress on Supportive and Palliative Care in Cancer, 8-15 / 10/17/89, Tehran**
- 12. Member of the Scientific and Executive Committee of the Conference on Thromboembolism and Cancer of the Iranian Cancer Association, 10/28/89, Tehran**
- 13. Member of the Scientific and Executive Committee of the Cancer Emergency Conference of the Iranian Cancer Association, 3/5/90, Tehran**
- 14. Scientific Secretary of Cancer Conference with Unknown Origin of Iranian Cancer Association, 6/5/90, Tehran**
- 15. Scientific Secretary of the Nursing Program of the 7th Annual Conference of the Iranian Cancer Association, 7/29/90/90, Tehran**
- 16. Scientific Secretary of the 13th Annual Conference on Iranian Pathology, 7/29/90/90, Tehran**
- 17. Member of the Scientific and Executive Committee of the Annual Clinical Oncology Conference of the Iranian Radiotherapy Society, 91, Tehran**
- 18. Member of the Scientific and Executive Committee of the Annual Clinical Oncology Conference of the Iranian Radiotherapy Society, 92, Tehran**
- 19. Member of the Scientific and Executive Committee of the Annual Clinical Oncology Conference of the Iranian Radiotherapy Society, 93, Tehran**
- 20. Scientific Secretary of the Conference on Thromboembolism and Cancer of the Iranian Radiotherapy Society, 5/23/93, Tehran**
- 21. Member of the Scientific Committee of Jihad University Breast Cancer Congress, 92, Tehran**
- 22. Member of the Scientific Committee of Jihad University Breast Cancer Congress, 93, Tehran**

- 23. Scientific Secretary of Immunoconference Conference, 3/12/96, Tehran**
- 24. Member of the Scientific and Executive Committee of WACC 2016 , Iranian Cancer Association , November 2016, Tehran**
- 25. Member of the Scientific and Executive Committee of WACC 2017 , Iranian Cancer Association , November 2017, Tehran**
- 26. Member of the Scientific and Executive Committee of WACC 2019 , Iranian Cancer Association , February 2019, Tehran**
- 27. Member of the Scientific Committee of 1<sup>st</sup> National congress on inflammation ,Immunology and inflammatory disorders, February 2019, Tehran**
- 28. Member of the Scientific and Executive Committee of the 3rd international Clinical Oncology Conference of the Iranian Radiotherapy Society, 2018, Tehran**

**Workshop (EDC):**

- 1. Certificate Of Attendance In Basic Good Clinical Practice Training Program, 26th - 27th, 2013, Akademika International Institute .Turkey**
- 2. Attending the 3-day training workshop on curriculum planning from 25 to 27 January 2012 in the Faculty of Rehabilitation Sciences, Shahid Beheshti University of Medical Sciences**
- 3. Attending a 4-day training workshop on teaching methods from 2-3-9-10 January 2012, which was held by the Center for Studies and Development of Shahid Beheshti University of Medical Sciences**
- 4. Attending a 1-day workshop on organizational ethics and patient satisfaction management was held on May 6, at Shahid Beheshti University of Medical Sciences**
- 5. Attending a 2-day workshop on professional ethics was held at Shahid Beheshti University of Medical Sciences**
- 6. Attending a 1-day workshop on Hemovigilance was held on 2 April 2016 at Tehran**

- 7. Attending a 1-day workshop on Brain Death was held on 9 April 2015 at Imam Hosein Hospital ,Tehran**
- 8. Attending a 3-day workshop on Tariff writing (radiotherapy codes for coding Iran's oncology radiotherapy services) was held from 10-12 October 2013 at Tehran**
- 9. Attending a 1-day workshop on OVID information data was held at Imam Hosein Hospital ,Tehran**
- 10. Attending a 1-day workshop on EBM was held in 25 September 2016 at Tehran**
- 11. Certificate Of Attendance In needment to be recognized as NETWORK, January 5th, 2011, Nooran Telecommunication, Tehran-Iran**
- 12. Passing the course of introductory student evaluation methods in the second semester of the academic year 91-92 in the master's degree program of medical education, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences**
- 13. Passing the course of teaching methods in the second semester of the 91-92 academic year in the master's degree program of medical education, Faculty of Medical Education, Shahid Beheshti University of Medical Sciences**
- 14. Passing the basic communication skills course in the second semester of the 91-92 academic year in the master's degree program of medical education, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences**
- 15. Passing the evaluation course of the introductory program in the second semester of the 91-92 academic year in the master's degree program of medical education, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences**
- 16. Passing the introductory course planning course in the second semester of the 91-92 academic year in the master's degree program of medical education, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences**
- 17. Passing the course of computer application in education 1 in the second semester of the academic year of 1991-92 in the master's degree program of medical education, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences**
- 18. Passing the advanced course planning course in the first semester of the 92-93 academic year in the master's degree program of medical education, Faculty of Medical Education, Shahid Beheshti University of Medical Sciences**
- 19. Passing the course of learning and teaching patterns in the first semester of the 92-93 academic year in the master's degree program of medical education, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences**



20. **Passing the course of computer application in education 2 in the first semester of the 92-93 academic year in the master's degree program of medical education, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences**
21. **Passing the course of quantitative methods of research in education in the first semester of the 92-93 academic year in the master's degree program of medical education, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences**
22. **Passing the course of qualitative methods of research in education in the first semester of the 92-93 academic year in the master's degree program of medical education, Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences**

### **Research Project**

1. **Collaborator in the National Research Project to investigate the prevalence and causes of occupational depression (Burnout) in caregivers of cancer patients of the Iranian Cancer Society**
2. **Collaborator in a Research Project to study the causes and problems of patients with cancer and its relationship with socio-economic factors in Iran Cancer Society of Iran**
3. **Collaborator in a Research Project on the relationship between mRNA genes of TS & ERCC1 genes with clinical pathological features and tumor location in gastrointestinal cancers of the Iranian Cancer Society**
4. **Collaborator in Tinagrast clinical trial Research Project (Ariatinagen) compared to Neupogen (Amgen) for the prevention of fever and neutropenia caused by chemotherapy in Cancer Patients**
5. **Collaborator in a Research Project to study the clinical and pathological features and common treatments of gastric and breast cancer in Iran, Iranian Cancer Society**
6. **Collaborator in a Research Project to investigate the response to treatment and the ability of resuscitation with chemotherapy in comparison with preoperative chemoradiation with a diet containing two taxol in cancer patients of the Iranian Cancer Society**
7. **Executer of Research Project of Pharmacokinetics Assessment Of Paclitaxel® Formulation And Compared to Abraxane® Formulation In Patients With Solid Tumors**
8. **Executer of Research Project PDLASTA Formulation study Post-marketing**

- 9. Executor of Research Project of The value of DW-MRI in predicting pathologic complete response (pCR) after neoadjuvant chemoradiation in patient with rectal cancer who referred to Imam Hossein hospital during July 2018 to July 2019**
- 10. Executor of Research Project of Evaluation of treatment outcomes of induction chemotherapy and then Neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer**
- 11. Collaborator in a Research Project of the predictive value of cardiac biochemical markers including high sensitive cardiac troponin-I (HSC-T-I), NT-Pro-BNP and two dimensional echocardiography in early detection of acute and sub acute cardiac toxicity in patients who are treated by anthracycline drug.**
- 12. Collaborator in a Research Project of A comparison survey on the combination Aprepitant - dexamethasone - Ondansetron, vs. Placebo-dexamethasone - Ondansetron, for prevention of Moderate Emetogenic Chemotherapy Regimens- Induced Nausea and Vomiting**
- 13. Collaborator in a Research Project of Evaluation of Estrogen, Progesterone & HER2 receptor in Iranian population of Breast Cancer**

### **Guideline**

- 1. Breast Cancer Guideline , Member of the Oncology Guideline Committee in Ministry of Health**
- 2. Colon Cancer Guideline , Member of the Oncology Guideline Committee in Ministry of Health**
- 3. Bevacizumab Drug Guideline , Member of the Oncology Guideline Committee in Ministry of Health**
- 4. Imatinib Drug Guideline , Member of the Oncology Guideline Committee in Ministry of Health**
- 5. Pemetrexed Drug Guideline , Member of the Oncology Guideline Committee in Ministry of Health**
- 6. Sorafenib Drug Guideline , Member of the Oncology Guideline Committee in Ministry of Health**
- 7. Liposomal Doxorubicin Drug Guideline , Member of the Oncology Guideline Committee in Ministry of Health**
- 8. Temozolomide Drug Guideline , Member of the Oncology Guideline Committee in Ministry of Health**

- 9. Bortezomib Drug Guideline , Member of the Oncology Guideline Committee in Ministry of Health**
- 10. Rituximab Drug Guideline , Member of the Oncology Guideline Committee in Ministry of Health**
- 11. Management of Oncologic patients in Corona Pandemic , Member of the Oncology Guideline Committee in Ministry of Health**
- 12. Prostate Cancer Guideline , Member of the Guideline Committee of Uro oncology in SBMU Urology research center**
- 13. Testicular Cancer Guideline , Member of the Guideline Committee of Uro oncology in SBMU Urology research center**
- 14. Kidney Cancer Guideline , Member of the Guideline Committee of Uro oncology in SBMU Urology research center**
- 15. Bladder Cancer Guideline , Member of the Guideline Committee of Uro oncology in SBMU Urology research center**

## **Media**

- 1. Due to the importance of the mass media in the prevention and early detection of cancer, about 100 live TV programs have been recorded and broadcast on the health network under the title of heart rate.**
- 2. Meanwhile, about 200 trailers were recorded for a few minutes as intermediate programs, which were repeatedly broadcast on the health network.**
- 3. social network is very important in new world, so live interview with fuscous on oncologic topic plan, weekly in Instagram app**

## **ACTIVITIES IN ONCOLOGY FIELD:**

- 1. Visit and follow up on 6000 cancer patients, of which about 350 newly diagnosed patients are visited and treated.**
- 2. Treatment of cancer patients with various radiotherapy and oncology devices, including brachytherapy, 6 & 18 MV accelerator**

**3. Treatment of cancer patients with various chemotherapy , hormone therapy & immunotherapy protocols**

**4. Active participation in the training of radiotherapy and oncology assistants in the form of journal club, review of reference books, in the clinic and on patients' beds, grand round and holding written exams and OSCE**

**5. Active participation in the Grand Round of the Oncology Hematology Department of Taleghani Hospital affiliated to Shahid Beheshti University of Medical Sciences**

### **Favorites**

- **Gastrointestinal cancer**
- **Breast cancer**
- **Molecular biology of cancer**
- **IMRT**
- **Radioisotopes**
- **Journalism in oncology**